Asset Details
Do you wish to reserve the book?
Futibatinib: First Approval
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Futibatinib: First Approval
Do you wish to request the book?
Futibatinib: First Approval
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Futibatinib: First Approval
2022
Overview
Futibatinib (Lytgobi
®
) is an oral, covalently binding, irreversible inhibitor of fibroblast growth factor receptor (FGFR)1–4 that is being developed by Taiho Oncology and Taiho Pharmaceutical for the treatment of cancers, including cholangiocarcinoma, breast cancer, gastric cancer, urothelial cancer, oesophageal cancer and non-small cell lung cancer. Futibatinib was approved in the USA on 30 September 2022 for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harbouring FGFR2 gene fusions or other rearrangements. This article summarizes the milestones in the development of futibatinib leading to this first approval.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Adult
/ Bile Duct Neoplasms - genetics
/ Bile Duct Neoplasms - metabolism
/ Bile Duct Neoplasms - pathology
/ Bile Ducts, Intrahepatic - metabolism
/ Bile Ducts, Intrahepatic - pathology
/ Carcinoma, Non-Small-Cell Lung - drug therapy
/ Carcinoma, Non-Small-Cell Lung - genetics
/ Cholangiocarcinoma - metabolism
/ Fibroblast growth factor receptor 2
/ Fibroblast growth factor receptors
/ Humans
/ Kinases
/ Medicine
/ Mutation
/ Non-small cell lung carcinoma
/ Oncology
/ Receptor, Fibroblast Growth Factor, Type 2
/ Tumors
